PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
36.42
+0.18 (+0.50%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close36.24
Open36.30
Bid0.00 x 0
Ask0.00 x 0
Day's Range36.03 - 36.42
52 Week Range29.83 - 36.60
Volume17,502,245
Avg. Volume17,157,303
Market Cap216.6B
Beta1.09
PE Ratio (TTM)26.64
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.28 (3.53%)
Ex-Dividend Date2017-11-09
1y Target EstN/A
Trade prices are not sourced from all markets
  • There's no reason for investors to sell stocks now: NYSE trader
    Yahoo Finance Video4 days ago

    There's no reason for investors to sell stocks now: NYSE trader

    Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Alexis Christoforous from the floor of the New York Stock Exchange to discuss current headwinds for US equities, including the nomination of a new (or same) Federal Reserve Chair in a few weeks.

  • Buyers never came in that Monday in '87—it was chaos: NYSE trader
    Yahoo Finance Video4 days ago

    Buyers never came in that Monday in '87—it was chaos: NYSE trader

    Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Alexis Christoforous from the New York Stock Exchange to discuss his firsthand account of what it was like on the floor that day.

  • I'm bullish on American Express and Verizon: NYSE trader
    Yahoo Finance Video4 days ago

    I'm bullish on American Express and Verizon: NYSE trader

    Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Alexis Christoforous from the floor of the New York Stock Exchange to discuss the latest Q3 earnings. Disclosure: Verizon is Yahoo Finance's parent company, and Alan Valdes owns shares of the company.

  • Glaxo (GSK) Q3 Earnings: Will it Deliver a Beat Yet Again?
    Zacks3 days ago

    Glaxo (GSK) Q3 Earnings: Will it Deliver a Beat Yet Again?

    The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair .

  • 3 High-Yield Pharmaceutical Stocks
    Motley Fool3 days ago

    3 High-Yield Pharmaceutical Stocks

    High-yield pharma stocks are rare, but these three offer comparatively fat payouts.

  • Market Realist3 days ago

    What’s Driving Economic Moats

    "How Moats Translate into Sustainable Competitive Advantages" is a five-part moat investing education series that explores the primary sources of economic moats.

  • Healthcare ETFs Head to Head: XLV vs. VHT
    Zacks3 days ago

    Healthcare ETFs Head to Head: XLV vs. VHT

    Head to head comparison of two Healthcare ETFs, XLV and VHT.

  • 3 Reasons to Stay Away From Valeant Pharmaceuticals Intl Inc Stock
    InvestorPlace4 days ago

    3 Reasons to Stay Away From Valeant Pharmaceuticals Intl Inc Stock

    During the past six months or so, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has been regaining some of its footing. CEO Joe Papa has wasted little time in cutting costs, streamlining the business and unloading of VRX stock’s assets. Since April, VRX stock has rallied from $8.60 to $12.81.

  • Conatus Entrusts Keith W. Marshall With Key Management Roles
    Zacks4 days ago

    Conatus Entrusts Keith W. Marshall With Key Management Roles

    Conatus Pharmaceuticals (CNAT) announced the appointment of Keith W. Marshall as executive vice president, chief operating officer and chief financial officer.

  • Barrons.com4 days ago

    4 Cheap Stock Picks for the Impatient

    General Motors stock has a rare combination of a breakdown valuation and zippy price momentum. That is, it trades at eight times forward earnings estimates, making it less than half as expensive as the ...

  • Market Realist4 days ago

    Inside Pfizer’s Performance in 3Q17

    PFE stock rose ~7.3% in 3Q17 and has risen ~11.3% YTD (year-to-date) as of October 16.

  • 2 Great Stocks For Retirees
    Motley Fool4 days ago

    2 Great Stocks For Retirees

    Find out what makes this pair of big pharma stocks a perfect fit for recent retirees looking to bolster their income.

  • 3 High-Yield Stocks for Conservative Investors
    Motley Fool4 days ago

    3 High-Yield Stocks for Conservative Investors

    These solid businesses with great dividend yields hit the sweet spot for conservative investors.

  • The Wall Street Journal4 days ago

    [$$] Reckitt Makeover Clears Way for Pfizer Bid

    The London-listed consumer group is doing what activist Nelson Peltz wants Procter & Gamble to do—but M&A may be an ulterior motive.

  • What to Expect from Big Pharmas After J&J's Solid Q3 Results?
    Zacks4 days ago

    What to Expect from Big Pharmas After J&J's Solid Q3 Results?

    Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.

  • Here's Why Ignyta Stock Soared as Much as 27.5% Today
    Motley Fool5 days ago

    Here's Why Ignyta Stock Soared as Much as 27.5% Today

    The biopharma's lead drug candidate has strong potential based on a sneak peek at midstage trial data.

  • Dow Jones Industrial Average Hits 23,000. Now What?
    InvestorPlace5 days ago

    Dow Jones Industrial Average Hits 23,000. Now What?

    On Oct. 18, the Dow Jones Industrial Average hit a new all-time intraday high of 23,145 as of this writing. Investors who aren’t playing the indices can gain exposure to the Dow Jones today through the SPDR Dow Jones Industrial Average ETF (NYSEARCA:DIA). With the index up 16.3% in 2017, though, how much longer can this rally continue?

  • Reckitt to reshape as sales growth evaporates
    Reuters5 days ago

    Reckitt to reshape as sales growth evaporates

    Britain's Reckitt Benckiser will split its business into two divisions -- consumer healthcare and home and hygiene products -- to try to revive sales that are set to stall this year. It hopes to improve performance in its newly expanded health business, while bringing greater focus and accountability to its slower-growth home and hygiene business. Reckitt, whose products range from Durex condoms to Lysol disinfectant, has blamed fallout from a cyber attack, a failed product launch and a safety scandal in South Korea for its lacklustre sales.

  • Financial Times5 days ago

    [$$] Reckitt Benckiser: fission for compliments

    In the physics of business, the entropic forces that break down a system can also liberate energy. Hidden value is meant to be released from spin-offs and the like, especially when profit growth slows. ...

  • Reuters5 days ago

    Reckitt to reshape as sales growth evaporates

    Britain's Reckitt Benckiser will split its business into two divisions -- consumer healthcare and home and hygiene products -- to try to revive sales that are set to stall this year. The change follows ...

  • Pfizer's Advil May Be Just the Thing for Sickly Reckitt
    Bloomberg5 days ago

    Pfizer's Advil May Be Just the Thing for Sickly Reckitt

    The problem is getting shareholders to back a cash call to pay for it.

  • Reuters5 days ago

    Reckitt Benckiser to form two business units for better focus

    Reckitt Benckiser (RB.L) plans to reorganise its business into two distinct units, one for health and the other for hygiene and home products, as it tries to improve its flagging performance. The maker of Durex condoms, Nurofen tablets and Dettol cleaners announced the restructuring on Wednesday, along with its third-quarter sales figures. The British company made the decision to restructure after its June acquisition of U.S. baby formula maker Mead Johnson, which will account for roughly half of the larger health unit's sales.

  • Reckitt CEO Focuses on Health, Looking Beyond Worst Year
    Bloomberg5 days ago

    Reckitt CEO Focuses on Health, Looking Beyond Worst Year

    Reckitt Benckiser Group Plc separated its home-care and health businesses, sharpening its focus on brands such as Durex condoms and Enfamil baby formula after a second cut in the sales forecast this year....

  • Forbes5 days ago

    Tiny Ignyta's Lung Cancer Drug Bested Pfizer's. Probably. Will We Ever Know For Sure?

    Results of a 32-patient study of a drug made by Ignyta Pharmaceuticals, a San Diego-based drugmaker, are a best case scenario for the company. The drug shrank tumors in 79% of patients and kept workingabout 10 months longer than the current drug, Pfizer’s Xalkori, did in earlier clinical trials.